Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions

Description:

Recent Biotech Funding, Deals and Partnerships

Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic.

This report, Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector.

Included in the report's coverage are the following data points

- 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential
- Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions)
- Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions)
- Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
- Number of Biotech Series A Companies by Indication Oncology, Platform Discovery, Diagnostics, CNS, Autoimmune
- Biotech Total Deal Value, 2005-2012
- IPO Statistics
- Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013

Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs.

This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma.

The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with executives and analysts.

The following are among the companies covered in this report:

- Abbott
- AC Immune SA
- Adimab
- Aileron Therapeutics Inc.
- Atara Biotherapeutics
- Cellectis
- Clarus Ventures
- CoStim Pharmaceuticals
- Covagen AG
- Dicerna Pharmaceuticals Inc.
- Editas Medicine
- Enanta Pharmaceuticals Inc.
- Endocyte Inc.
Evotec
Forma Therapeutics
Galapagos NV
Mannkind Corp.
Melinta Therapeutics
Micromet
Novartis
OncoMed
Onyx Pharmaceuticals Inc.
Otonomy Inc.
Pharmasset
Seattle Genetics Inc.
Royalty Pharma
Roche
Sutro Biopharma Inc.
Thesan Pharmaceuticals Inc.
UCB Inc.
Voyager Therapeutics
Xenon Pharmaceuticals Inc.
Xoma Corp.

Contents:
1.0 EXECUTIVE SUMMARY
1.1 Key Findings
1.2 Methodology
2.0 INTRODUCTION
2.1 Reason for the Report
2.1.1 Why Investing Is Important
2.1.2 Beyond the Seed Stage
2.1.3 Identify Value Drivers
3.0 TRENDS AND EXPECTATIONS
3.1 Corporate Venture Capital Spurs M&A Activity
3.2 Licensing Deals to Grow
3.3 Venture Capital's Strong Outlook
3.4 Therapeutic Areas of Focus
3.4.1 The Outcomes Push
3.5 In Need of New Strategies
3.5.1 Modeling Potential Success
3.5.2 Crowdfunding
3.5.2.1 A Lifeline
4.0 GROWTH THROUGH SOPHISTICATED COLLABORATIONS
4.1 Determining Product Value
4.1.1 Quantifiable Issues
4.1.2 Revolutionary Value
4.1.3 Global Value
4.2 Changing Roles and Market Landscapes
5.0 VENTURE CAPITAL VS. CORPORATE CAPITAL
5.1 New Fundraising Vistas
5.2 Venture Arms with a Strategy
5.3 Corporate Capital Fundamentals
6.0 INVESTMENT DOLLAR TRENDS
6.1 Annual Numbers
6.1.1 Trends in 2013
6.1.2 Trends in 2012
6.1.3 Trends in 2011
6.1.4 Trends in 2010
6.1.5 Trends in 2009
6.2 Personalized Medicine
7.0 KEY DEALS
7.1 Ablynx NV
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.2 Acetylon Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.3 AC Immune SA
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.4 Adimab
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.5 Aileron Therapeutics Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.6 Algeta ASA
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.7 Alios BioPharma Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.8 Alkermes
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.9 Alnylam Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.10 Amylin Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.11 Ardea Biosciences
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.12 Atara Biotherapeutics
<table>
<thead>
<tr>
<th>Description of Deal</th>
<th>Size</th>
<th>Agreement Type</th>
<th>Details</th>
<th>Therapeutic Background and Potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.13 Avila Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.14 Boston Biomedical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.15 Cellectis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.16 Clarus Ventures</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.17 CoStim Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.18 Covagen AG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.19 Dicerna Pharmaceuticals Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.20 Editas Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.21 Enanta Pharmaceuticals Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.22 Endocyte Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Details
Therapeutic Background and Potential
7.23 Evotec AG
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.24 Forma Therapeutics
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.25 Galapagos NV
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.26 Gemin X Pharmaceuticals
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.27 Genmab
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.28 GlaxoSmithKline
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.29 Human Genome Sciences
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.30 immatics Biotechnologies GmbH
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.31 Inhibitex
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.32 Inhibrx
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.33 Isis Pharmaceuticals Inc.
<table>
<thead>
<tr>
<th>Description of Deal</th>
<th>Size</th>
<th>Agreement Type</th>
<th>Details</th>
<th>Therapeutic Background and Potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.34 Juno Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.35 Macrogenics Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.36 Mannkind Corp.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.37 Medigene AG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.38 Melinta Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.39 Merck</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.40 Mesoblast Ltd.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.41 Micromet AG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.42 Moderna Therapeutics Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.43 OncoMed Pharmaceuticals Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.44 Onyx Pharmaceuticals Inc.</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.45 Otonomy Inc.</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.46 Pharmasset</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.47 Plexxikon Inc.</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.48 Reata Pharmaceuticals</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.49 Royalty Pharma</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.50 Seattle Genetics Inc.</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.51 Sutro Biopharma Inc.</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.52 Thesan Pharmaceuticals Inc.</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.53 UCB Inc.</td>
<td>Description of Deal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>Agreement Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td>Therapeutic Background and Potential</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.54 Voyager Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.55 Xenon Pharmaceuticals Inc.
Description of Deal
Size
Agreement Type
Details
Therapeutic Background and Potential
7.56 Xoma Corp.
Description of Deal
Size
Agreement Type
Details
LIST OF EXHIBITS
1.0 EXECUTIVE SUMMARY
Summary Exhibit: Biotechnology Investment Dollars, 2012 and 2013 ($ millions)
6.0 INVESTMENT DOLLAR TRENDS
Exhibit 1: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
Exhibit 2: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
Exhibit 3: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
Exhibit 4: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
Exhibit 5: Breakdown of Overall and Biotech Venture Capital Dollars, Billions of Dollars US Invested in 2013
Exhibit 6: Venture Capital Dollar Trends, Biotechnology Dollars Invested by Quarter, 2009-2013
Exhibit 7: Health Care as a Percentage of Total Venture Investment, 2009-2012
Exhibit 8: Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
Exhibit 9: Number of Biotech Series A Companies by Indication, 2009, Raising More than $2 Million
Exhibit 10: Number of Biotech Series A Companies by Indication, 2010, Raising More Than $2 Million
Exhibit 11: Number of Biotech Series A Companies by Indication, 2011, Raising More Than $2 Million
Exhibit 12: Number of Biotech Series A Companies by Indication, 2012, Raising More Than $2 Million
Exhibit 13: Biotech Total Deal Value, 2005-2012, Minimum Two Big Exits
Exhibit 14: Personalized Medicine M&A with Disclosed Values, 2010-2013
Exhibit 15: Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013
Exhibit 16: Personalized Medicine Disclosed M&A Deal Value by Focus, 2010-2013
Exhibit 17: Personalized Medicine Financings, 2010-2013
Exhibit 18: Personalized Medicine Financings by Type, Number of Deals, 2010-2013
Exhibit 19: Personalized Medicine Financings by Category, Number of Deals, 2010-2013

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2874884/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions
Web Address: http://www.researchandmarkets.com/reports/2874884/
Office Code: SCBRXLXQ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 7000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World